Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 5/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6521442 | 0.87 | CYP2C19 (0.62) | CYP2D6KMT2AALDH1A1MEN1POLB | |
| SCHEMBL2702763 | 0.85 | CYP2D6 (0.64) | CYP2D6KMT2AALDH1A1MEN1MAPK1 | |
| SCHEMBL6521612 | 0.83 | FAAH (0.50) | CYP2D6KMT2AMAPK1GAA | |
| SCHEMBL7824315 | 0.81 | CYP2D6 (1.00) | CYP2D6KMT2AALDH1A1MEN1MAPK1 | |
| SCHEMBL8877209 | 0.80 | CYP2D6 (0.57) | CYP2D6KMT2AALDH1A1MEN1POLB | |
| SCHEMBL6519623 | 0.79 | CYP2D6 (0.56) | CYP2D6KMT2AALDH1A1MEN1MAPK1 | |
| SCHEMBL27757118 | 0.78 | CYP2D6 (0.58) | CYP2D6KMT2AALDH1A1MEN1MAPK1 | |
| SCHEMBL11888956 | 0.78 | CYP2D6 (0.71) | CYP2D6KMT2AALDH1A1MEN1MAPK1 | |
| SCHEMBL6519705 | 0.78 | CYP2D6 (0.71) | CYP2D6KMT2AALDH1A1MEN1MAPK1 | |
| SCHEMBL8877723 | 0.77 | CYP2D6 (0.57) | CYP2D6KMT2AALDH1A1MEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102498099-B | HSL inhibitors useful in the treatment of diabetes | HOFFMAN-LA ROCHE LTD. (CH) | 2014-10-29 | — | — | CN | claimed |
| EP-2475644-B1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | claimed |
| US-8258158-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | claimed |
| EP-2475644-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | claimed |
| CN-102498099-A | HSL inhibitors useful in the treatment of diabetes | HOFFMANN LA ROCHE | 2012-06-13 | — | — | CN | claimed |
| WO-2011029808-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | claimed |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | claimed |
| CN-102498099-B | HSL inhibitors useful in the treatment of diabetes | HOFFMAN-LA ROCHE LTD. (CH) | 2014-10-29 | — | — | CN | disclosed |
| EP-2475644-B1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8258158-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2475644-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| CN-102498099-A | HSL inhibitors useful in the treatment of diabetes | HOFFMANN LA ROCHE | 2012-06-13 | — | — | CN | disclosed |
| WO-2011029808-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LIPE, PNLIP, LPL | CYP2D6 2042/4885KMT2A 3947/4885ALDH1A1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.